Company profile: ADC Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted oncology therapies, developing antibody-drug conjugates and non-ADC products for hematological cancers and solid tumors using proprietary PBD-dimer technology. Offerings include ZYNLONTA (CD19 ADC), the LOTIS clinical trial program, ADCT-602 (CD22 ADC for acute lymphoblastic leukemia), Mipasetamab uzoptirine/ADCT-601 (AXL-targeting), PBD-dimer technology, and support for investigator-initiated trials.
Products and services
- ZYNLONTA (Loncastuximab Tesirine-lpyl): CD19-targeted ADC for hematological cancers, using latest-generation PBD-dimer payload to disrupt cancer-cell DNA processes and induce cell death with targeted cytotoxicity
- PBD-dimer technology: Proprietary technology used in ADCs to create potent DNA cross-links within cancer cells, triggering lethal cytotoxicity and enabling highly targeted antitumor activity
- Mipasetamab uzoptirine (ADCT-601): AXL-targeting ADC for various solid tumors and hematologic malignancies, custom-engineered to disrupt intracellular DNA and selectively kill tumor cells via targeted delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ADC Therapeutics
Maverick Therapeutics
HQ: United States
Website
- Description: Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maverick Therapeutics company profile →
Kairos Therapeutics
HQ: Canada
Website
- Description: Provider of a proprietary next-generation antibody-drug conjugate platform as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kairos Therapeutics company profile →
Ab Initio Biotherapeutics
HQ: United States
Website
- Description: Provider of antigen discovery and antibody generation solutions using a proprietary platform targeting multi-transmembrane proteins such as GPCRs, supporting therapeutics for neurological, cardiovascular, endocrine and gastrointestinal disorders; offerings include antibody optimization, single B-cell screening of immune repertoires, the OmniAb Discovery Platform, OmniRat and OmniMouse with high-throughput screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ab Initio Biotherapeutics company profile →
Synthon
HQ: The Netherlands
Website
- Description: Provider of affordable generic medicines and pharmaceutical development and manufacturing services, including API development, formulation development (solid oral dose, immediate and modified release, injectables), high-containment compounds for cancer treatment, R&D across multiple countries, and global manufacturing of tablets, capsules, and injectables.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synthon company profile →
Faron Pharmaceuticals
HQ: Finland
Website
- Description: Provider of clinical-stage biopharmaceutical therapies targeting acute organ trauma, vascular damage, and cancer immunotherapy, including bexmarilimab, a humanized monoclonal antibody against Clever-1 on macrophages to modify the tumor microenvironment and boost anti-tumor immune response, and Traumakine, an intravenous interferon beta-1a to prevent multiorgan dysfunction and mitigate CAR-T side effects (cytokine release syndrome, neurotoxicity).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Faron Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ADC Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ADC Therapeutics
2.2 - Growth funds investing in similar companies to ADC Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ADC Therapeutics
4.2 - Public trading comparable groups for ADC Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →